116 completed, 28 terminated, 7 withdrawn, 6 active not recruiting. 173 Phase 1, 39 Phase 2.
Follow Mycosis Fungoides: new trials by email Literature Review of Mycosis Fungoides trials Research Report on Mycosis Fungoides
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome Biospecimen Collection, Computed Tomography, Cosibelimab - Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome | Phase 1 | Not yet recruiting | City of Hope Medical Center | 14 | 2027-05-16 | 2026-11-09 |
| A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides Duvelisib - Mycosis Fungoides, Cutaneous T-cell Lymphoma | Phase 1 | Not yet recruiting | SecuraBio | 30 | 2027-01-01 | 2026-07-20 |
| A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors MDSY-1240 - Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC) | Phase 1 / Phase 2 | Not yet recruiting | Medsyn Biopharma, LLC | 75 | 2026-11-01 | 2026-10-27 |
| A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma KK2223 - T-cell NHL (PTCL or CTCL) | Phase 1 | Recruiting | Kyowa Kirin, Inc. | 72 | 2026-09-02 | 2026-09-30 |
| A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) Cyclophosphamide, Fludarabine, Autologous CCR4 CAR T cells - Relapsed and/or Refractory Mature T Cell Malignancy, Peripheral T-Cell Lymphoma | Phase 1 | Suspended | National Cancer Institute (NCI) | 60 | 2025-09-29 | 2026-10-16 |
| BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma Cemiplimab - Mycosis Fungoides | Phase 1 / Phase 2 | Withdrawn | AHS Cancer Control Alberta | 2024-12-01 | 2025-06-27 | |
| Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome Tulmimetostat - Mycosis Fungoides, Sezary Syndrome | Phase 1 | Active not recruiting | Washington University School of Medicine | 24 | 2024-01-09 | 2026-09-16 |
| Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Biopsy - Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | Mayo Clinic | 21 | 2024-01-05 | 2026-07-01 |
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma Fenretinide - T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | SciTech Development, Inc. | 46 | 2023-12-18 | 2026-10-05 |
| A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) BMS-986369 - Relapsed or Refractory T-cell Lymphomas | Phase 1 / Phase 2 | Active not recruiting | Bristol-Myers Squibb | 83 | 2023-11-20 | 2026-10-07 |
| Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides Mogamulizumab, Brentuximab vedotin - Cutaneous T Cell Lymphoma, Mycosis Fungoides | Phase 1 | Suspended | University of Alabama at Birmingham | 10 | 2023-05-01 | 2026-06-15 |
| Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma. Pembrolizumab administered using the Sofusa® DoseConnect™ - Mycosis Fungoides | Phase 1 | Unknown | Sorrento Therapeutics, Inc. | 10 | 2022-08-31 | 2022-10-12 |
| A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides Bexarotene, Total Skin Electron Beam (TSEB) - Cutaneous T-cell Lymphoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2022-03-16 | 2026-02-04 |
| A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL MT-101, MT-101 + Conditioning (Lymphodepleting) Chemotherapy - Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous | Phase 1 / Phase 2 | Suspended | Myeloid Therapeutics | 40 | 2021-12-15 | 2023-11-13 |
| Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome Biospecimen Collection, Computed Tomography, Duvelisib - Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 19 | 2021-10-21 | 2026-11-04 |
| A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat [14C]-resminostat - Cutaneous T Cell Lymphoma, Mycosis Fungoides | Phase 1 | Completed | 4SC AG | 5 | 2021-10-12 | 2022-02-18 |
| Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment - Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Emory University | 5 | 2021-04-21 | 2024-08-13 |
| Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment Biospecimen Collection, Computed Tomography, Magrolimab - Mycosis Fungoides, Recurrent Mycosis Fungoides | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 8 | 2021-04-06 | 2025-10-16 |
| Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine - Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 45 | 2020-07-18 | 2026-09-30 |
| Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome Recombinant human Interleukin-15 (rhIL-15), Mogamulizumab - Adult T-Cell Lymphoma/Leukemia, Sezary Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 6 | 2020-02-26 | 2023-01-04 |
Showing 20 of 173. Sign in to see all of them.
Lymphoma, T-Cell, Cutaneous (150) · Sezary Syndrome (149) · Lymphoma, Follicular (110) · Lymphoma, Large B-Cell, Diffuse (107) · Leukemia, Lymphocytic, Chronic, B-Cell (105) · Lymphoma, Mantle-Cell (105) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (105) · Lymphoma, B-Cell, Marginal Zone (103) · Burkitt Lymphoma (102) · Lymphoma, Large-Cell, Anaplastic (102) · Lymphoma, Non-Hodgkin (100) · Hodgkin Disease (99) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (98) · Lymphoma, Large-Cell, Immunoblastic (93)
Hemic and Lymphatic Diseases (173) · Neoplasms by Histologic Type (173) · Immunoproliferative Disorders (172) · Lymphatic Diseases (172) · Immune System Diseases (171) · Lymphoproliferative Disorders (166) · Neoplasms (163) · Lymphoma, T-Cell (155) · Hematologic Diseases (120) · Leukemia, Lymphoid (118) · Lymphoma, B-Cell (114) · Pathological Conditions, Signs and Symptoms (114) · Pathologic Processes (113) · Disease Attributes (112) · Chronic Disease (105)
fludarabine phosphate (12) · Cyclophosphamide (11) · Peripheral Blood Stem Cell Transplantation (11) · Bortezomib (8) · Filgrastim (7) · Lenalidomide (7) · Magnetic Resonance Spectroscopy (7) · Tacrolimus (7) · Etoposide (6) · Gemcitabine (6) · Vorinostat (6) · fludarabine (6) · romidepsin (6) · Cyclosporine (5) · Disulfides (5)
National Cancer Institute (NCI) (41) · City of Hope Medical Center (8) · Mayo Clinic (8) · Northwestern University (8) · Memorial Sloan Kettering Cancer Center (7) · National Institutes of Health Clinical Center (CC) (7) · Fred Hutchinson Cancer Center (6) · M.D. Anderson Cancer Center (6) · BioCryst Pharmaceuticals (3) · Case Comprehensive Cancer Center (3) · Jonsson Comprehensive Cancer Center (3) · Stanford University (3) · UNC Lineberger Comprehensive Cancer Center (3) · University of Medicine and Dentistry of New Jersey (3) · Wake Forest University Health Sciences (3)
United States (159) · Canada (8) · Italy (5) · Germany (2) · South Korea (2) · France (1) · Japan (1) · Poland (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Shivaani Kummar, MD (4) · Barbara Pro, MD (3) · Roger Strair, MD, PhD (3) · Abhinav Deol, M.D. (2) · Alex Shalaurov, MD, PhD (2) · Elma Baron, MD (2) · Kenneth G. Lucas, MD (2) · Kyoo H. Lee, MD (2) · Mario Sznol, MD (2) · Oleg E Akilov, MD, PhD (2) · Ramesh Ramanathan (2) · Richard K. Burt, MD (2) · Ronald Levy (2) · Thomas E. Witzig, MD (2) · William K. Kelly, DO (2)
PMID 22045986, PMID 32499241, PMID 32632956, PMID 33883258, PMID 35175355, PMID 10552943, PMID 10764422, PMID 11410496, PMID 11675364, PMID 11895901, PMID 14630685, PMID 16135477, PMID 17020988, PMID 17119113, PMID 17515522, PMID 18327587, PMID 18463792, PMID 18645136, PMID 19451403, PMID 19789320, PMID 20697067, PMID 21247755, PMID 21498721, PMID 22259028, PMID 23256542, PMID 23393050, PMID 24241210, PMID 24474568, PMID 24530972, PMID 26210442, PMID 26659919, PMID 26853648, PMID 26943915, PMID 28199478, PMID 28270022, PMID 28314788, PMID 29292843, PMID 29572391, PMID 29622656, PMID 30562587, PMID 31617432, PMID 31689242, PMID 32508818, PMID 33072126, PMID 33236943, PMID 33492438, PMID 34519839, PMID 34627593, PMID 36448227, PMID 36826995
P30CA015083 (4), P30CA033572 (4), U01CA062491 (4), U01CA062502 (4), U01CA076576 (4), U01CA099168 (4), P30CA008748 (3), P30CA014520 (3), P30CA015704 (3), P30CA016058 (3), P30CA016672 (3), P30CA043703 (3), P30CA072720 (3), U01CA062487 (3), U01CA062505 (3)